

, Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-9 (Cancelled)

10 (Currently Amended). A method for therapeutic treatment to induce G-CSF production or secretion in a subject in need thereof, comprising administering to the subject an amount of an A3-selective adenosine A3 receptor agonist (A3RAg) in a manner such that it exerts its prime effect through the adenosine A3 receptor, the amount being effective to selectively agonize the adenosine A3 receptor so as to induce G-CSF production or secretion.


11 (Cancelled)

12 (Previously Presented). A method according to Claim 10, wherein the drug is administered orally.

13-14 (Cancelled)


15 (Currently Amended). A method according to Claim 10, wherein said active ingredient is an A3-selective A3RAg that is a nucleotide-nucleoside derivative of the following general formula (I):

, Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004



wherein

- R₁ is C₁-C₁₀ alkyl, C₁-C₁₀ hydroxyalkyl, C₁-C₁₀ carboxyalkyl or C₁-C₁₀ cyanoalkyl or a group of the following general formula (II):




in which:

- Y is an oxygen or sulfur atom or CH₂;
- X₁ is H, C₁-C₁₀ alkyl, R^aR^bNC(=O)- or HOR^c-, wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and R^c is selected from the group consisting of C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl;

, Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004

- X_2 is H, hydroxyl, C_1-C_{10} alkylamino, C_1-C_{10} alkylamido or C_1-C_{10} hydroxyalkyl;
 - X_3 and X_4 each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, $-OCOPh$, $-OC(=S)OPh$ or both X_3 and X_4 are oxygen connected to $>C=S$ to form a 5-membered ring, or X_2 and X_3 form the ring of formula (III):




where R' and R'' are independently C_1-C_{10} alkyl;

- R_2 is selected from the group consisting of hydrogen, halo, C_1-C_{10} alkylether, amino, hydrazido, C_1-C_{10} alkylamino, C_1-C_{10} alkoxy, C_1-C_{10} thioalkoxy, pyridylthio, C_2-C_{10} alkenyl; C_2-C_{10} alkynyl, thio, and C_1-C_{10} alkylthio; and

- R_3 is a $-NR_4R_5$ group with R_4 being hydrogen, alkyl, substituted alkyl or aryl-NH-C(Z)-, with Z being O, S or NR^a, and, when R_4 is hydrogen, R_5 being selected from the group consisting of R- and S-1-phenylethyl, benzyl, phenylethyl or anilide groups, each such group being unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C_1-C_{10} alkyl, amino,

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004


halo, C₁-C₁₀, haloalkyl, nitro, hydroxyl, acetamido, C₁-C₁₀ alkoxy, and sulfonic acid or a salt thereof; or R₅ being benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β-alanylaminobenzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C₁-C₁₀ cycloalkyl; or R₅ being a group of the following formula:



or, when R₄ is alkyl, substituted alkyl, or aryl-NH-C(Z)-, then R₅ being selected from the group consisting of substituted or unsubstituted heteroaryl-NR^a-C(Z), heteroaryl-C(Z)-, alkaryl-NR^a-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z); or a suitable salt of the compound defined above.

16 (Currently Amended). A method according to Claim 15, wherein said active ingredient is an A3-selective A3RAg that is a nucleoside derivative of the general formula (IV):

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004



in which X_1 , R_2 and R_5 are as defined in Claim 15.

17 (Original). A method according to Claim 16, wherein said active ingredient is an N^6 -benzyladenosine-5'-uronamide.

18 (Previously Presented). A method according to Claim 17, wherein said active ingredient is selected from the group consisting of N^6 -2-(4-aminophenyl)ethyladenosine (APNEA), N^6 -(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide) (AB-MECA) and 1-deoxy-1-{6-[({3-iodophenyl}methyl)amino]-9H-purine-9-yl}-N-methyl- β -D-ribofuranuronamide (IB-MECA) and 2-chloro- N^6 -(3-iodobenzyl)adenosine-5'-N-methyluronamide (Cl-IB-MECA).

19-40 (Cancelled)

41 (Previously Presented). A method for inhibiting abnormal cell proliferation in a subject in need thereof, comprising administering to the subject an amount of an A3-

, Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

selective adenosine A3 receptor agonist (A3RAg), in a manner such that it exerts its prime effect through the adenosine A3 receptor, the amount being effective to selectively inhibit abnormal cell proliferation.


42 (Original). A method according to Claim 41, for inhibiting growth or proliferation of tumor cells.

43 (Cancelled)

44 (Previously Presented). A method according to Claim 41, wherein the drug is administered orally.

45 (Original). A method according to Claim 41, wherein the drug is administered in combination with a chemotherapeutic drug.


46 (Currently Amended). A method according to Claim 4541, wherein said active ingredient is an A3-selective A3RAG that is a nucleotide-nucleoside derivative of the following general formula (I):



wherein

Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004

- R₁ is C₁-C₁₀ alkyl, C₁-C₁₀ hydroxyalkyl, C₁-C₁₀ carboxyalkyl or C₁-C₁₀ cyanoalkyl or a group of the following general formula (II) :




in which:

- Y is an oxygen or sulfur atom or CH₂;
- X₁ is H, C₁-C₁₀ alkyl, R^aR^bNC(=O)- or HOR^c-, wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and R^c is selected from the group consisting of C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl;
- X₂ is H, hydroxyl, C₁-C₁₀ alkylamino, C₁-C₁₀ alkylamido or C₁-C₁₀ hydroxyalkyl;
- X₃ and X₄ each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, -OCOPh, -OC(=S)OPh or both X₃ and X₄ are oxygen

, Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

connected to >C=S to form a 5-membered ring, or X₂ and X₃ form the ring of formula (III):




where R' and R'' are independently C₁-C₁₀ alkyl;

- R₂ is selected from the group consisting of hydrogen, halo, C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀ thioalkoxy, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio; and


- R₃ is a -NR₄R₅ group with R₄ being hydrogen, alkyl, substituted alkyl or aryl-NH-C(Z)-, with Z being O, S or NR^a, and, when R₄ is hydrogen, R₅ being selected from the group consisting of R- and S-1-phenylethyl, benzyl, phenylethyl or anilide groups, each said group being unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C₁-C₁₀ alkyl, amino, halo, C₁-C₁₀ haloalkyl, nitro, hydroxyl, acetamido, C₁-C₁₀ alkoxy, and sulfonic acid or a salt thereof; or R₅ being benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β-alanylaminobenzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C₁-C₁₀ cycloalkyl; or R₅ being a group of the following formula:

Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004



or, when R₄ is alkyl, substituted alkyl, or aryl-NH-C(Z)-, then R₅ being selected from the group consisting of substituted or unsubstituted heteroaryl-NR^a-C(Z), heteroaryl-C(Z)-, alkaryl-NR^a-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z); or a suitable salt of the compound defined above.

47 (Currently Amended). A method according to Claim 46, wherein said active ingredient is an A3-selective A3RAg that is a nucleoside derivative of the general formula (IV):



in which X₁, R₂ and R₅ are as defined in Claim 46.

48 (Original). A method according to Claim 47, wherein said active ingredient is an N⁶-benzyladenosine-5'-uronamide.

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

49 (Previously Presented). A method according to Claim 48, wherein said active ingredient is selected from the group consisting of N⁶-2-(4-aminophenyl)ethyladenosine (APNEA), N⁶-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide (AB-MECA) and 1-deoxy-1-{6-[{3-iodophenyl}methyl]amino}-9H-purine-9-yl}-N-methyl-β-D-ribofuranuronamide (IB-MECA) and 2-chloro-N⁶-(3-iodobenzyl)adenosine-5'-N-methyluronamide (Cl-IB-MECA).

50 (Previously Presented). A method for treating cancer in a subject in need thereof, comprising administering to the subject an amount of an A3-selective adenosine A3 receptor agonist (A3RAg), in a manner such that it exerts its prime effect through the adenosine A3 receptor, the amount being effective to both selectively inhibit proliferation of cancer cells and to counter toxic side effects of chemotherapeutic drug treatment of the same subject.


51 (Previously Presented). A method according to Claim 50, wherein the A3RAg synergizes with said drug to yield a stronger anti-tumor effect.

52 (Original). A method according to Claim 50, wherein the drug is administered orally.

53 (Currently Amended). A method according to Claim 50, wherein said active ingredient is an A3-selective A3RAg


Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004

that is a nucleotide-nucleoside derivative of the following general formula (I):



wherein

- R₁ is C₁-C₁₀ alkyl, C₁-C₁₀ hydroxyalkyl, C₁-C₁₀ carboxyalkyl or C₁-C₁₀ cyanoalkyl or a group of the following general formula (II):




in which:

- Y is an oxygen or sulfur atom or CH₂;
- X₁ is H, C₁-C₁₀ alkyl, R^aR^bNC(=O)- or HOR^c-, wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and R^c is selected from

Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004

the group consisting of C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl,
 C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl;

- X₂ is H, hydroxyl, C₁-C₁₀ alkylamino, C₁-C₁₀ alkylamido or C₁-C₁₀ hydroxyalkyl;
 - X₃ and X₄ each independently are hydrogen,
 hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy,
 nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester,
 thioether, -OCOPh, -OC(=S)OPh or both X₃ and X₄ are oxygen
 connected to >C=S to form a 5-membered ring, or X₂ and X₃ form
 the ring of formula (III):




where R' and R'' are independently C₁-C₁₀ alkyl;

- R₂ is selected from the group consisting of
 hydrogen, halo, C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀
 alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀ thioalkoxy, pyridylthio, C₂-C₁₀
 alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio; and

- R₃ is a -NR₄R₅ group with R₄ being hydrogen, alkyl,
 substituted alkyl or aryl-NH-C(Z)-, with Z being O, S or NR^a,
 and, when R₄ is hydrogen, R₅ being selected from the group
 consisting of R- and S-1-phenylethyl, benzyl, phenylethyl or
 anilide groups, each said group being unsubstituted or

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004


substituted in one or more positions with a substituent selected from the group consisting of C₁-C₁₀ alkyl, amino, halo, C₁-C₁₀ haloalkyl, nitro, hydroxyl, acetamido, C₁-C₁₀ alkoxy, and sulfonic acid or a salt thereof; or R₅ being benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β-alanylaminobenzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C₁-C₁₀ cycloalkyl; or R₅ being a group of the following formula:



or, when R₄ is alkyl, substituted alkyl, or aryl-NH-C(Z)-, then R₅ being selected from the group consisting of substituted or unsubstituted heteroaryl-NR^a-C(Z), heteroaryl-C(Z)-, alkaryl-NR^a-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z); or a suitable salt of the compound defined above.

54 (Currently Amended). A method according to Claim 53, wherein said active ingredient is an A3-selective A3RAg that is a nucleoside derivative of the general formula (IV):

Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004



in which X₁, R₂ and R₅ are as defined in Claim 53.

55 (Original). A method according to Claim 54,
 wherein said active ingredient is an N⁶-benzyladenosine-5'-
 uronamide.

56 (Previously Presented). A method according to
 Claim 55, wherein said active ingredient is selected from the
 group consisting of N⁶-2-(4-aminophenyl)ethyladenosine (APNEA),
 N⁶-(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide) (AB-
 MECA) and 1-deoxy-1-{6-[({3-iodophenyl}methyl)amino]-9H-
 purine-9-yl}-N-methyl-β-D-ribofuranuronamide (IB-MECA) and 2-
 chloro-N⁶-(3-iodobenzyl)adenosine-5'-N-methyluronamide (Cl-IB-
 MECA).

57 (Currently Amended). A method for inhibiting
 abnormal cell proliferation in a subject, comprising
 administering to the subject an amount of an adenosine A3
 receptor agonist (A3RAG) in a manner such that it exerts its

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004


prime effect through the A₃ adenosine receptor without essentially activating adenosine receptors other than the A₃ adenosine receptor, the amount being effective to selectively inhibit abnormal cell proliferation.

58 (Previously Presented). A method according to Claim 41, wherein said abnormal cell proliferation is the growth or proliferation of tumor cells.

59 (Previously Presented). A method according to Claim 57, wherein the drug is administered orally.


60 (Previously Presented). A method according to Claim 57, wherein the drug is administered in combination with a chemotherapeutic drug.

61 (Currently Amended). A method according to Claim 57, wherein the active ingredient is an A₃RAg that exerts its prime effect through the A₃ adenosine receptor without essentially activating adenosine receptors other than the A₃ adenosine receptor, which is a nucleotide-nucleoside derivative of the following general formula (I):



Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004

wherein R₁ is C₁-C₁₀ alkyl, C₁-C₁₀ hydroxyalkyl, C₁-C₁₀ carboxyalkyl or C₁-C₁₀ cyanoalkyl or a group of the following general formula (II):




in which:

- Y is an oxygen or sulfur atom or CH₂;
- X₁ is H, C₁-C₁₀ alkyl, R^aR^bNC(=O)- or HOR^c-, wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and R^c is selected from the group consisting of C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, C₁-C₁₀ BOC-aminoalkyl, and C₃-C₁₀ cycloalkyl;
- X₂ is H, hydroxyl, C₁-C₁₀ alkylamino, C₁-C₁₀ alkylamido or C₁-C₁₀ hydroxyalkyl;
- X₃ and X₄ each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, -OCOPh, -OC(=S)OPh or both X₃ and X₄ are oxygen

Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004

connected to >C=S to form a 5-membered ring, or X₂ and X₃ form the ring of formula (III):




where R' and R'' are independently C₁-C₁₀ alkyl;

- R₂ is selected from the group consisting of hydrogen, halo, C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀ thioalkoxy, pyridylthio, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio; and


- R₃ is a -NR₄R₅ group with R₄ being hydrogen, alkyl, substituted alkyl or aryl-NH-C(Z)-, with Z being O, S or NR^a, and, when R₄ is hydrogen, R₅ being selected from the group consisting of R- and S-1-phenylethyl, benzyl, phenylethyl or anilide groups, each said group being unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C₁-C₁₀ alkyl, amino, halo, C₁-C₁₀ haloalkyl, nitro, hydroxyl, acetamido, C₁-C₁₀ alkoxy, and sulfonic acid or a salt thereof; or R₅ being benzodioxanemethyl, fururyl, L-propylalanyl-aminobenzyl, β-alanylaminobenzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C₁-C₁₀ cycloalkyl; or R₅ being a group of the following formula:

Appln. No. 09/700,751
 Amdt. dated July 21, 2004
 Supplementing Amendment of January 12, 2004



or, when R₄ is alkyl, substituted alkyl, or aryl-NH-C(Z)-, then R₅ is selected from the group consisting of substituted or unsubstituted heteroaryl-NR^a-C(Z)-, heteroaryl-C(Z)-, alkaryl-NR^a-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z)-; or a suitable salt of said nucleotide derivative.

62 (Currently Amended). A method according to Claim 61, wherein said active ingredient is an A3RAg that exerts its prime effect through the A3 adenosine receptor without essentially activating adenosine receptors other than the A3 adenosine receptor, which is a nucleoside derivative of the general formula (IV):



in which X₁, R₂ and R₄ are as defined in Claim 61.

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

63 (Previously Presented). A method according to Claim 62, wherein said active ingredient is an N⁶-benzyladenosine-5'-uronamide.

64 (Previously Presented). A method according to Claim 63, wherein said active ingredient is selected from the group consisting of N⁶-2-(4-aminophenyl)ethyladenosine (APNEA), N⁶-(4-amino-3-iodobenzyl) adenosine-5'- (N-methyluronamide) (AB-MECA) and 1-deoxy-1-{6-[({3-iodophenyl} methyl)amino]-9H-purine-9-yl}-N-methyl-β-D-ribofuranuron-amide (IB-MECA) and 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methly-uronamide (Cl-IB-MECA).

65 (Previously Presented). A method according to Claim 57, wherein the active ingredient is administered at an amount less than 100 µg/Kg body weight.

66 (Previously Presented). A method according to Claim 65, wherein the amount is less than 50 µg/Kg body weight.

67 (Previously Presented). A method according to claim 15, wherein said active ingredient is selected from the group consisting of:

N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-9-hydroxyethyladenine;
R-N⁶-(3-iodobenzyl)-9-(2,3-dihydroxypropyl)adenine;
S-N⁶-(3-iodobenzyl)-9-(2,3-dihydroxypropyl)adenine;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N⁶-(3-iodobenzyladenin-9-yl)acetic acid;
N⁶-(3-iodobenzyl)-9-(3-cyanopropyl)adenine;
2-chloro-N⁶-(3-iodobenzyl)-9-methyladenine;
2-amino-N⁶-(3-iodobenzyl)-9-methyladenine;
2-hydrazido-N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-2-methylamino-9-methyladenine;
2-dimethylamino-N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-9-methyl-2-propylaminoadenine;
2-hexylamino-N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-2-methoxy-9-methyladenine;
N⁶-(3-iodobenzyl)-9-methyl-2-methylthioadenine;
N⁶-(3-iodobenzyl)-9-methyl-2-(4-pyridylthio)adenine;
(1S,2R,3S,4R)-4-(6-amino-2-phenylethylamino-9H-purin-9-yl)cyclopentane-1,2,3-triol;
(1S,2R,3S,4R)-4-(6-amino-2-chloro-9H-purin-9-yl)cyclopentane-1,2,3-triol;
(±)-9-[2α,3α-dihydroxy-4β-(N-methylcarbamoyl)cyclopent-1β-yl)]-N⁶-(3-iodobenzyl)-adenine;
2-chloro-9-(2'-amino-2',3'-dideoxy-β-D-5'-methyl-arabino-furonamido)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(2',3'-dideoxy-2'-fluoro-β-D-5'-methyl-arabino-furonamido)-N⁶-(3-iodobenzyl)adenine;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

9-(2-acetyl-3-deoxy- β -D-5-methyl-ribofuronamido)-2-chloro-N⁶(3-iodobenzyl)adenine;

2-chloro-9-(3-deoxy-2-methanesulfonyl- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;

2-chloro-9-(3-deoxy- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;

2-chloro-9-(3,5-1,1,3,3-tetraisopropyldisiloxyl- β -D-5-ribofuranosyl)-N⁶-(3-iodobenzyl)adenine;

2-chloro-9-(2',3'-O-thiocarbonyl- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;

9-(2-phenoxythiocarbonyl-3-deoxy- β -D-5-methyl-ribofuronamido)-2-chloro-N⁶-(3-iodobenzyl)adenine;

1-(6-benzylamino-9H-purin-9-yl)-1-deoxy-N,4-dimethyl- β -D-ribofuranosiduronamide;

2-chloro-9-(2,3-dideoxy- β -D-5-methyl-ribofuronamido)-N⁶-benzyladenine;

2-chloro-9-(2'-azido-2',3'-dideoxy- β -D-5'-methyl-arabino-furonamido)-N⁶-benzyladenine;

2-chloro-9-(β -D-erythrofuranoside)-N⁶-(3-iodobenzyl)adenine;

N⁶-(benzodioxanemethyl)adenosine;

1-(6-furfurylamino-9H-purin-9-yl)-1-deoxy-N-methyl- β -D-ribofuranosiduronamide;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N^6 -[3-(L-proylamino)benzyl]adenosine-5'-N-methyluronamide;

N^6 -[3-(β -alanylarnino)benzyl]adenosine-5'-N-methyluronamide;

N^6 -[3-(N-T-Boc- β -alanylarnino)benzyl]adenosine-5'-N-methyluronamide

6-(N'-phenylhydrazinyl)purine-9- β -ribofuranoside-5'-N-methyluronamide;

6-(O-phenylhydroxylarnino)purine-9- β -ribofuranoside-5'-N-methyluronamide;

9-(β -D-2',3'-dideoxyerythrocyanosyl)- N^6 -[(3- β -alanylarnino)benzyl]adenosine;

9-(β -D-erythrocyanoside)-2-methylarnino-N 6 -(3-iodobenzyl)adenine;

2-chloro-N-(3-iodobenzyl)-9-(2-tetrahydrofuryl)-9H-purin-6-amine;

2-chloro-(2'-deoxy-6'-thio-L-arabinosyl)adenine;

2-chloro-(6'-thio-L-arabinosyl)adenine;

N^6 -(4-biphenyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;

N^6 -(2,4-dichlorobenzyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;

N^6 -(4-methoxyphenyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N^6 - (4-chlorophenyl-carbonylamino)-adenosine-5'-N-ethyluronamide;

N^6 - (phenyl-carbonylamino)-adenosine-5'-N-ethyluronamide;

N^6 - (benzylcarbamoylamino)-adenosine-5'-N-ethyluronamide;

N^6 - (4-sulfonamido-phenylcarbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 - (4-acetyl-phenylcarbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 - ((R)- α -phenylethylcarbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 - ((S)- α -phenylethylcarbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 - (5-methyl-isoxazol-3-yl-carbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 - (1,3,4-thiadiazol-2-yl-carbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 - (4-n-propoxy-phenylcarbamoyl)-adenosine-5'-N-ethyluronamide;

N^6 -bis-(4-nitrophenylcarbamoyl)-adenosine-5'-N-ethyluronamide; and

N^6 -bis-(5-chloro-pyridin-2-yl-carbamoyl)-adenosine-5'-N-ethyluronamide.

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

68 (Currently Amended). A method according to Claim 16, wherein said active ingredient is an A3 selective A3RAg that is selected from the group consisting of those of formula (IV) in which:

X₁ is R^aR^bNC(O), wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, and C₃-C₁₀ cycloalkyl, R₂ is selected from the group consisting of hydrogen, halo, C₁-C₁₀ alkyoxy, amino, C₂-C₁₀ alkenyl, and C₂-C₁₀ alkynyl, and R₅ is selected from the group consisting of R- and S-1-phenylethyl, an unsubstituted benzyl group, and a benzyl group substituted in one or more positions with a substituent selected from the group consisting of C₁-C₁₀ alkyl, amino, halo, C₁-C₁₀ haloalkyl, nitro, hydroxy, acetamido, C₁-C₁₀ alkoxy, and sulfo.

69 (Currently Amended). A method according to claim 68, wherein said active ingredient is an A3 selective A3RAg that is selected from the group consisting of those of formula (IV) in which:

R^a and R^b are the same or different and are selected from the group consisting of hydrogen and C₁-C₁₀ alkyl, and R₂ is hydrogen or halo;

R^a is hydrogen, R₂ is hydrogen and R₅ is unsubstituted benzyl;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

R^b is C₁-C₁₀ alkyl or C₃-C₁₀ cycloalkyl and R₅ in R- or S-1-phenylethyl or a benzyl substituted in one or more positions with a substituent selected from the group consisting of halo, amino, acetamido, C₁-C₁₀ haloalkyl and sulfo, wherein the sulfo derivative is a salt;

R₂ is a C₂-C₁₀ alkyne of the formula R^d-C=C- where R^d is a C₁-C₈ alkyl; or

R₂ is a halo, C₁-C₁₀ alkylamino, or C₁-C₁₀ alkylthio, R^a is hydrogen, R^b is C₁-C₁₀ alkyl and R₅ is a substituted benzyl.

70 (Currently Amended). A method according to Claim 15, wherein the active ingredient is an A3 selective A3RAg that is in the form of a triethylammonium salt.

71 (Previously Presented). A method according to claim 46, wherein said active ingredient is selected from the group consisting of:

N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-9-hydroxyethyladenine;
R-N⁶-(3-iodobenzyl)-9-(2,3-dihydroxypropyl)adenine;
S-N⁶-(3-iodobenzyl)-9-(2,3-dihydroxypropyl)adenine;
N⁶-(3-iodobenzyladenin-9-yl)acetic acid;
N⁶-(3-iodobenzyl)-9-(3-cyanopropyl)adenine;
2-chloro-N⁶-(3-iodobenzyl)-9-methyladenine;
2-amino-N⁶-(3-iodobenzyl)-9-methyladenine;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

2-hydrazido-N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-2-methylamino-9-methyladenine;
2-dimethylamino-N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-9-methyl-2-propylaminoadenine;
2-hexylamino-N⁶-(3-iodobenzyl)-9-methyladenine;
N⁶-(3-iodobenzyl)-2-methoxy-9-methyladenine;
N⁶-(3-iodobenzyl)-9-methyl-2-methylthioadenine;
N⁶-(3-iodobenzyl)-9-methyl-2-(4-pyridylthio)adenine;
(1S,2R,3S,4R)-4-(6-amino-2-phenylethylamino-9H-purin-9-yl)cyclopentane-1,2,3-triol;
(1S,2R,3S,4R)-4-(6-amino-2-chloro-9H-purin-9-yl)cyclopentane-1,2,3-triol;
(±)-9-[2α,3α-dihydroxy-4β-(N-methylcarbamoyl)cyclopent-1β-yl)]-N⁶-(3-iodobenzyl)-adenine;
2-chloro-9-(2'-amino-2',3'-dideoxy-β-D-5'-methylarabino-furonamido)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(2',3'-dideoxy-2'-fluoro-β-D-5'-methylarabino-furonamido)-N⁶-(3-iodobenzyl)adenine;
9-(2-acetyl-3-deoxy-β-D-5-methyl-ribofuronamido)-2-chloro-N⁶(3-iodobenzyl)adenine;
2-chloro-9-(3-deoxy-2-methanesulfonyl-β-D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;

Appn. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

2-chloro-9-(3-deoxy- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(3,5-1,1,3,3-tetraisopropyldisiloxyl- β -D-5-ribofuranosyl)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(2',3'-O-thiocarbonyl- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;
9-(2-phenoxythiocarbonyl-3-deoxy- β -D-5-methyl-ribofuronamido)-2-chloro-N⁶-(3-iodobenzyl)adenine;
1-(6-benzylamino-9H-purin-9-yl)-1-deoxy-N,4-dimethyl- β -D-ribofuranosiduronamide;
2-chloro-9-(2,3-dideoxy- β -D-5-methyl-ribofuronamido)-N⁶-benzyladenine;
2-chloro-9-(2'-azido-2',3'-dideoxy- β -D-5'-methyl-arabino-furonamido)-N⁶-benzyladenine;
2-chloro-9-(β -D-erythrofuranoside)-N⁶-(3-iodobenzyl)adenine;
N⁶-(benzodioxanemethyl)adenosine;
1-(6-furfurylamino-9H-purin-9-yl)-1-deoxy-N-methyl- β -D-ribofuranosiduronamide;
N⁶-[3-(L-prolylamino)benzyl]adenosine-5'-N-methyluronamide;
N⁶-[3-(β -alanylarnino)benzyl]adenosine-5'-N-methyluronamide;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N⁶-[3-(N-T-Boc-β-alanylarnino)benzyl]adenosine-5'-N-methyluronamide;
6-(N'-phenylhydrazinyl)purine-9-β-ribofuranoside-5'-N-methyluronamide;
6-(O-phenylhydroxylarnino)purine-9-β-ribofuranoside-5'-N-methyluronamide;
9-(β-D-2',3'-dideoxyerythrocyanosyl)-N⁶-[(3-β-alanylarnino)benzyl]adenosine;
9-(β-D-erythrocyanoside)-2-methylarnino-N⁶-(3-iodobenzyl)adenine;
2-chloro-N-(3-iodobenzyl)-9-(2-tetrahydrofuryl)-9H-purin-6-amine;
2-chloro-(2'-deoxy-6'-thio-L-arabinosyl)adenine;
2-chloro-(6'-thio-L-arabinosyl)adenine;
N⁶-(4-biphenyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;
N⁶-(2,4-dichlorobenzyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;
N⁶-(4-methoxyphenyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;
N⁶-(4-chlorophenyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;
N⁶-(phenyl-carbonylarnino)-adenosine-5'-N-ethyluronamide;

Appn. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N^6 - (benzylcarbamoylamino) -adenosine-5'-N-

ethyluronamide;

N^6 - (4-sulfonamido-phenylcarbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 - (4-acetyl-phenylcarbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 - ((R)- α -phenylethylcarbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 - ((S)- α -phenylethylcarbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 - (5-methyl-isoxazol-3-yl-carbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 - (1,3,4-thiadiazol-2-yl-carbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 - (4-n-propoxy-phenylcarbamoyl) -adenosine-5'-N-

ethyluronamide;

N^6 -bis-(4-nitrophenylcarbamoyl) -adenosine-5'-N-

ethyluronamide; and

N^6 -bis-(5-chloro-pyridin-2-yl-carbamoyl) -adenosine-

5'-N-ethyluronamide.

72 (Previously Presented). A method according to claim 53, wherein said active ingredient is selected from the group consisting of:

N^6 - (3-iodobenzyl) -9-methyladenine;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N^6 - (3-iodobenzyl) -9-hydroxyethyladenine;
 $R-N^6$ - (3-iodobenzyl) -9- (2,3-dihydroxypropyl) adenine;
 $S-N^6$ - (3-iodobenzyl) -9- (2,3-dihydroxypropyl) adenine;
 N^6 - (3-iodobenzyladenin-9-yl) acetic acid;
 N^6 - (3-iodobenzyl) -9- (3-cyanopropyl) adenine;
2-chloro- N^6 - (3-iodobenzyl) -9-methyladenine;
2-amino- N^6 - (3-iodobenzyl) -9-methyladenine;
2-hydrazido- N^6 - (3-iodobenzyl) -9-methyladenine;
 N^6 - (3-iodobenzyl) -2-methylamino-9-methyladenine;
2-dimethylamino- N^6 - (3-iodobenzyl) -9-methyladenine;
 N^6 - (3-iodobenzyl) -9-methyl-2-propylaminoadenine;
2-hexylamino- N^6 - (3-iodobenzyl) -9-methyladenine;
 N^6 - (3-iodobenzyl) -2-methoxy-9-methyladenine;
 N^6 - (3-iodobenzyl) -9-methyl-2-methylthioadenine;
 N^6 - (3-iodobenzyl) -9-methyl-2-(4-pyridylthio) adenine;
(1S,2R,3S,4R)-4- (6-amino-2-phenylethylamino-9H-purin-9-yl)cyclopentane-1,2,3-triol;
(1S,2R,3S,4R)-4- (6-amino-2-chloro-9H-purin-9-yl)cyclopentane-1,2,3-triol;
(\pm) -9- [2 α ,3 α -dihydroxy-4 β - (N-methylcarbamoyl)cyclopent-1 β -yl)]- N^6 - (3-iodobenzyl) -adenine;
2-chloro-9- (2'-amino-2',3'-dideoxy- β -D-5'-methylarabino-furonamido)- N^6 - (3-iodobenzyl) adenine;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

2-chloro-9-(2',3'-dideoxy-2'-fluoro- β -D-5'-methyl-arabino-furonamido)-N⁶-(3-iodobenzyl)adenine;
9-(2-acetyl-3-deoxy- β -D-5-methyl-ribofuronamido)-2-chloro-N⁶(3-iodobenzyl)adenine;
2-chloro-9-(3-deoxy-2-methanesulfonyl- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(3-deoxy- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(3,5-1,1,3,3-tetraisopropyldisiloxyl- β -D-5-ribofuranosyl)-N⁶-(3-iodobenzyl)adenine;
2-chloro-9-(2',3'-O-thiocarbonyl- β -D-5-methyl-ribofuronamido)-N⁶-(3-iodobenzyl)adenine;
9-(2-phenoxythiocarbonyl-3-deoxy- β -D-5-methyl-ribofuronamido)-2-chloro-N⁶-(3-iodobenzyl)adenine;
1-(6-benzylamino-9H-purin-9-yl)-1-deoxy-N₄-dimethyl- β -D-ribofuranosiduronamide;
2-chloro-9-(2,3-dideoxy- β -D-5-methyl-ribofuronamido)-N⁶-benzyladenine;
2-chloro-9-(2'-azido-2',3'-dideoxy- β -D-5'-methyl-arabino-furonamido)-N⁶-benzyladenine;
2-chloro-9-(β -D-erythrofuranoside)-N⁶-(3-iodobenzyl)adenine;
N⁶-(benzodioxanemethyl)adenosine;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

1-(6-furfurylamino-9H-purin-9-yl)-1-deoxy-N-methyl-
 β -D-ribofuranosiduronamide;

N^6 -[3-(L-prolylamino)benzyl]adenosine-5'-N-
methyluronamide;

N^6 -[3-(β -alanylaminobenzyl]adenosine-5'-N-
methyluronamide;

N^6 -[3-(N-T-Boc- β -alanylaminobenzyl]adenosine-5'-N-
methyluronamide

6-(N'-phenylhydrazinyl)purine-9- β -ribofuranoside-5'-
N-methyluronamide;

6-(O-phenylhydroxylamino)purine-9- β -ribofuranoside-
5'-N-methyluronamide;

9-(β -D-2',3'-dideoxyerythofuranosyl)- N^6 -[(3- β -
alanylaminobenzyl]adenosine;

9-(β -D-erythofuranoside)-2-methylamino- N^6 -(3-
iodobenzyl)adenine;

2-chloro-N-(3-iodobenzyl)-9-(2-tetrahydrofuryl)-9H-
purin-6-amine;

2-chloro-(2'-deoxy-6'-thio-L-arabinosyl)adenine;

2-chloro-(6'-thio-L-arabinosyl)adenine;

N^6 -(4-biphenyl-carbonylamino)-adenosine-5'-N-
ethyluronamide;

N^6 -(2,4-dichlorobenzyl-carbonylamino)-adenosine-5'-N-
ethyluronamide;

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N⁶- (4-methoxyphenyl-carbonylamino) -adenosine-5'-N-ethyluronamide;

N⁶- (4-chlorophenyl-carbonylamino) -adenosine-5'-N-ethyluronamide;

N⁶- (phenyl-carbonylamino) -adenosine-5'-N-ethyluronamide;

N⁶- (benzylcarbamoylamino) -adenosine-5'-N-ethyluronamide;

N⁶- (4-sulfonamido-phenylcarbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶- (4-acetyl-phenylcarbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶- ((R)- α -phenylethylcarbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶- ((S)- α -phenylethylcarbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶- (5-methyl-isoxazol-3-yl-carbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶- (1,3,4-thiadiazol-2-yl-carbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶- (4-n-propoxy-phenylcarbamoyl) -adenosine-5'-N-ethyluronamide;

N⁶-bis- (4-nitrophenylcarbamoyl) -adenosine-5'-N-ethyluronamide; and

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

N⁶-bis-(5-chloro-pyridin-2-yl-carbamoyl)-adenosine-
5'-N-ethyluronamide.

73 (Currently Amended). A method according to Claim 46, wherein the active ingredient is an A3 selective A3RAg that is in the form of a triethylammonium salt.

74 (Currently Amended). A method according to Claim 53, wherein the active ingredient is an A3 selective A3RAg that is in the form of a triethylammonium salt.

75 (Currently Amended). A method according to Claim 47, wherein said active ingredient is an A3 selective A3RAg that is selected from the group consisting of those of formula (IV) in which:

X₁ is R^aR^bNC(O), wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, and C₃-C₁₀ cycloalkyl, R₂ is selected from the group consisting of hydrogen, halo, C₁-C₁₀ alkoxy, amino, C₂-C₁₀ alkenyl, and C₂-C₁₀ alkynyl, and R₄ is selected from the group consisting of R- and S-1-phenylethyl, an unsubstituted benzyl group, and a benzyl group substituted in one or more positions with a substituent selected from the group consisting of C₁-C₁₀ alkyl, amino, halo, C₁-C₁₀ haloalkyl, nitro, hydroxy, acetamido, C₁-C₁₀ alkoxy, and sulfo.

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

76 (Currently Amended). A method according to claim
7675, wherein said active ingredient is an A3 selective A3RAg
that is selected from the group consisting of those of formula
(IV) in which:

R^a and R^b are the same or different and are selected
from the group consisting of hydrogen and C₁-C₁₀ alkyl, and R₂
is hydrogen or halo;

R^a is hydrogen, R₂ is hydrogen and R₅ is
unsubstituted benzyl;

R^b is C₁-C₁₀ alkyl or C₃-C₁₀ cycloalkyl and R₅ in R- or
S-1-phenylethyl or a benzyl substituted in one or more
positions with a substituent selected from the group
consisting of halo, amino, acetamido, C₁-C₁₀ haloalkyl and
sulfo, wherein the sulfo derivative is a salt;

R₂ is a C₂-C₁₀ alkyne of the formula R^d-C=C- where R^d
is a C₁-C₈ alkyl; or

R₂ is a halo, C₁-C₁₀ alkylamino, or C₁-C₁₀ alkylthio,
R^a is hydrogen, R^b is C₁-C₁₀ alkyl and R₅ is a substituted
benzyl.

77 (Currently Amended). A method according to Claim
54, wherein said active ingredient is an A3 selective A3RAg
that is selected from the group consisting of those of formula
(IV) in which:

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

X₁ is R^aR^bNC(O), wherein R^a and R^b may be the same or different and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, amino, C₁-C₁₀ haloalkyl, C₁-C₁₀ aminoalkyl, and C₃-C₁₀ cycloalkyl, R₂ is selected from the group consisting of hydrogen, halo, C₁-C₁₀ alkyoxy, amino, C₂-C₁₀ alkenyl, and C₂-C₁₀ alkynyl, and R₄ is selected from the group consisting of R- and S-1-phenylethyl, an unsubstituted benzyl group, and a benzyl group substituted in one or more positions with a substituent selected from the group consisting of C₁-C₁₀ alkyl, amino, halo, C₁-C₁₀ haloalkyl, nitro, hydroxy, acetamido, C₁-C₁₀ alkoxy, and sulfo.

78 (Currently Amended). A method according to claim 7877, wherein said active ingredient is an A3 selective A3RAg that is selected from the group consisting of those of formula (IV) in which:

R^a and R^b are the same or different and are selected from the group consisting of hydrogen and C₁-C₁₀ alkyl, and R₂ is hydrogen or halo;

R^a is hydrogen, R₂ is hydrogen and R₅ is unsubstituted benzyl;

R^b is C₁-C₁₀ alkyl or C₃-C₁₀ cycloalkyl and R₅ in R- or S-1-phenylethyl or a benzyl substituted in one or more positions with a substituent selected from the group

Appln. No. 09/700,751
Amdt. dated July 21, 2004
Supplementing Amendment of January 12, 2004

consisting of halo, amino, acetamido, C₁-C₁₀ haloalkyl and sulfo, wherein the sulfo derivative is a salt;

R₂ is a C₂-C₁₀ alkyne of the formula R^a-C=C- where R^a is a C₁-C₈ alkyl; or

R₂ is a halo, C₁-C₁₀ alkylamino, or C₁-C₁₀ alkylthio, R^a is hydrogen, R^b is C₁-C₁₀ alkyl and R₅ is a substituted benzyl.

79 (Previously Presented). A method for inhibiting abnormal cell proliferation in a subject in need thereof, comprising administering to the subject an adenosine A₃ receptor agonist (A₃RAg) in an amount of less than 100 µg/Kg body weight.

80 (Previously Presented). A method according to Claim 79 wherein the amount of the A₃RAg is less than 50 µg/kg body weight.